Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ICP DAS Biomedical Polymers, commonly branded as ICP DAS-BMP, is a Taiwan-based manufacturer and supplier of medical-grade thermoplastic polyurethane materials for medical device applications. The business was established by ICP DAS after a 2018 TPU technology transfer agreement with ITRI and markets itself as Asia's first medical-grade TPU manufacturer. Its portfolio includes Alithane, Durathane, and Arothane TPU series, including customized colors, hardness profiles, and radiopaque formulations using tungsten or barium sulfate. The company operates TPU R&D, production, and testing laboratories, emphasizes smart-factory and IIoT-enabled manufacturing, and holds ISO 13485 certification with USP Class VI and/or ISO 10993-tested materials. Rather than developing therapeutics, the company serves medical device OEMs in areas such as cardiology, urology, orthodontics, wound care, catheter systems, guidewires, and implant-related applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ICP DAS Biomedical Polymers.